Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Female patients with histological or cytological proven diagnosis of breast cancer
Stage IV disease
Performance Status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Scale
Patients had to have previously received anthracycline based regimens as a adjuvant therapy or neo-adjuvant chemotherapy and then progressed and developed metastatic disease
Adequate organ function
You may not be if
Prior chemotherapy for metastatic disease
Previous radiation therapy is allowed but must not have included whole pelvis radiation
Known or suspected brain metastasis. Serious concomitant disorders that would compromise the safety of the patient or compromise the patient's ability to complete the study, at the discretion of the investigator
Concurrent administration of any other tumor therapy, including cytotoxic chemotherapy, hormonal therapy and immunotherapy (including trastuzumab (Herceptin))
Peripheral neuropathy of Common Toxicity Criteria (CTC) Grade greater than 1. History of significant neurological or mental disorder, including seizures or dementia
Clareo Health | Gemcitabine Combinations in Metastatic Breast Cancer (MBC), 1st Line
